Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 CelsionOragenicsMonopar Therapeutics180 Life SciencesReviva Pharmaceuticals
Price Information
Current Price$1.21$0.78$5.15$11.98$4.96
52 Week RangeHoldHoldBuyN/AN/A
Overall Score1.
Analysis Score3.
Community Score2.
Dividend Score0.
Ownership Score0.
Earnings & Valuation Score0.
Analyst Ratings
Consensus RecommendationHoldHoldBuyN/AN/A
Consensus Price Target$4.00N/A$30.00N/AN/A
% Upside from Price Target230.58% upsideN/A482.52% upsideN/AN/A
Trade Information
Market Cap$90.77 million$85.52 million$64.72 million$216.02 million$45.79 million
Average Volume18,452,32623,123,379272,6822,946,69330,830
Sales & Book Value
Annual Revenue$500,000.00N/AN/AN/AN/A
Price / Sales181.55N/AN/AN/AN/A
CashflowN/AN/AN/AN/A$0.04 per share
Price / CashN/AN/AN/AN/A122.91
Book Value$0.63 per share$0.23 per share$1.19 per share$1.12 per share$0.60 per share
Price / Book1.92N/AN/AN/AN/A
Net Income$-16,850,000.00$-15,570,000.00$-4,220,000.00$-90,000.00$620,000.00
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/A
Net Margins-4,315.00%N/AN/AN/AN/A
Return on Equity (ROE)-104.32%-499.13%-42.84%-94.05%-13.34%
Return on Assets (ROA)-47.65%-178.75%-40.98%-38.77%-1.36%
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt-to-Equity Ratio0.25%N/AN/AN/A0.28%
Current Ratio3.67%9.55%29.65%0.18%0.05%
Quick Ratio3.67%9.55%29.65%0.18%0.05%
Ownership Information
Institutional Ownership Percentage13.73%12.75%0.66%7.11%64.11%
Insider Ownership Percentage20.49%9.90%48.40%73.50%20.60%
Shares Outstanding75.02 million109.65 million12.57 million18.03 million9.23 million
Next Earnings Date5/21/2021 (Estimated)5/21/2021 (Estimated)5/6/2021 (Estimated)N/A5/3/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
7/13/2020CelsionDawson JamesDowngrade
7/25/2019CelsionBrookline Capital ManagementReiterated Rating
6/2/2020OragenicsHC WainwrightDowngrade
1/28/2021Monopar TherapeuticsRoth CapitalInitiated Coverage
9/24/2020Monopar TherapeuticsMaxim GroupInitiated Coverage
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.